Literature DB >> 22844366

Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.

Shuyan Liu1, Zhengang Yuan, Chunyang Zhang, Weijun Fu, Jian Hou.   

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma (PTCL) subtype, accounting for 15-20% of PTCL and 2% of all non-Hodgkin lymphoma (NHL), with a poor prognosis. In the present study, we describe a 76-year-old patient with AITL who failed to respond to conventional chemotherapy but responded to bortezomib-based treatment and demonstrated persistent clinical improvement at the 18-month follow-up. These data suggest that bortezomib-based treatment may be a reliable, safe and effective alternative for treating relapsed/refractory AITL.

Entities:  

Year:  2012        PMID： 22844366      PMCID： PMC3402752          DOI： 10.3892/ol.2012.724

Source DB:  PubMed          Journal:  Oncol Lett        ISSN： 1792-1074            Impact factor:   2.967


  16 in total

1.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Authors:  J B Sunwoo; Z Chen; G Dong; N Yeh; C Crowl Bancroft; E Sausville; J Adams; P Elliott; C Van Waes
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.

Authors:  Nam H Dang; Barbara Pro; Fredrick B Hagemeister; Felipe Samaniego; Dan Jones; Barry I Samuels; Maria A Rodriguez; Andre Goy; Jorge E Romaguera; Peter McLaughlin; Ann T Tong; Francesco Turturro; Pamela L Walker; Luis Fayad
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

3.  Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.

Authors:  Francesco d'Amore; John Radford; Thomas Relander; Mats Jerkeman; Hervé Tilly; Anders Osterborg; Franck Morschhauser; Martin Gramatzki; Martin Dreyling; Bo Bang; Hans Hagberg
Journal:  Br J Haematol       Date:  2010-07-14       Impact factor: 6.998

4.  Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas.

Authors:  B Martínez-Delgado; M Cuadros; E Honrado; A Ruiz de la Parte; G Roncador; J Alves; J M Castrillo; C Rivas; J Benítez
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

5.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

Authors:  Owen A O'Connor; Barbara Pro; Lauren Pinter-Brown; Nancy Bartlett; Leslie Popplewell; Bertrand Coiffier; Mary Jo Lechowicz; Kerry J Savage; Andrei R Shustov; Christian Gisselbrecht; Eric Jacobsen; Pier Luigi Zinzani; Richard Furman; Andre Goy; Corinne Haioun; Michael Crump; Jasmine M Zain; Eric Hsi; Adam Boyd; Steven Horwitz
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

Review 6.  Advances in the understanding and management of angioimmunoblastic T-cell lymphoma.

Authors:  Laurence de Leval; Christian Gisselbrecht; Philippe Gaulard
Journal:  Br J Haematol       Date:  2009-12-04       Impact factor: 6.998

7.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

Authors:  Nathalie Mourad; Nicolas Mounier; Josette Brière; Emmanuel Raffoux; Alain Delmer; Alfred Feller; Chris J L M Meijer; Jean-François Emile; Réda Bouabdallah; André Bosly; Jacques Diebold; Corinne Haioun; Bertrand Coiffier; Christian Gisselbrecht; Philippe Gaulard
Journal:  Blood       Date:  2008-02-21       Impact factor: 22.113

8.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors:  Julie Vose; James Armitage; Dennis Weisenburger
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

9.  Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.

Authors:  J Lee; C Suh; H J Kang; B-Y Ryoo; J Huh; Y H Ko; H-S Eom; K Kim; K Park; W S Kim
Journal:  Ann Oncol       Date:  2008-08-09       Impact factor: 32.976

10.  Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

Authors:  Andrea Gallamini; Francesco Zaja; Caterina Patti; Atto Billio; Maria Rosaria Specchia; Alessandra Tucci; Alessandro Levis; Annunziata Manna; Vicenzo Secondo; Luigi Rigacci; Antonello Pinto; Emilio Iannitto; Valerio Zoli; Pierfederico Torchio; Stefano Pileri; Corrado Tarella
Journal:  Blood       Date:  2007-06-20       Impact factor: 22.113
View more
  2 in total

1.  Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature.

Authors:  Hua-Ping DU; Qian-Qian Yang; Y E Zhang
Journal:  Oncol Lett       Date:  2016-02-09       Impact factor: 2.967

2.  Bortezomib Use for a Critically Ill Patient with Angioimmunoblastic T-Cell Lymphoma.

Authors:  Motoharu Shibusawa
Journal:  Case Rep Hematol       Date:  2022-08-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.